Spero Therapeutics, Inc. (NASDAQ:SPRO) Expected to Announce Earnings of -$0.77 Per Share

Wall Street brokerages expect that Spero Therapeutics, Inc. (NASDAQ:SPROGet Rating) will report earnings per share (EPS) of ($0.77) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Spero Therapeutics’ earnings. The lowest EPS estimate is ($0.90) and the highest is ($0.56). Spero Therapeutics reported earnings per share of ($0.63) in the same quarter last year, which indicates a negative year over year growth rate of 22.2%. The company is expected to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Spero Therapeutics will report full-year earnings of ($2.88) per share for the current financial year, with EPS estimates ranging from ($3.34) to ($2.08). For the next fiscal year, analysts expect that the business will post earnings of ($1.98) per share, with EPS estimates ranging from ($2.82) to ($1.18). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Spero Therapeutics.

Spero Therapeutics (NASDAQ:SPROGet Rating) last announced its quarterly earnings data on Monday, May 16th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.14). Spero Therapeutics had a negative net margin of 792.03% and a negative return on equity of 116.93%. During the same period last year, the firm earned ($0.66) earnings per share.

Several analysts have recently commented on SPRO shares. Berenberg Bank downgraded shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 20th. HC Wainwright dropped their price target on shares of Spero Therapeutics from $37.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday. Cantor Fitzgerald reduced their price objective on shares of Spero Therapeutics from $27.00 to $5.00 in a research report on Tuesday, May 17th. Cowen downgraded shares of Spero Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 4th. Finally, Zacks Investment Research downgraded shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, April 5th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $23.69.

SPRO stock opened at $1.20 on Thursday. The stock has a market capitalization of $39.39 million, a P/E ratio of -0.37 and a beta of 1.87. Spero Therapeutics has a 12 month low of $1.19 and a 12 month high of $19.87. The firm has a 50-day moving average price of $5.08 and a 200-day moving average price of $9.89.

In related news, major shareholder Aquilo Capital Management, Llc purchased 39,727 shares of the business’s stock in a transaction on Tuesday, April 26th. The shares were acquired at an average price of $5.24 per share, for a total transaction of $208,169.48. Following the purchase, the insider now owns 5,321,231 shares of the company’s stock, valued at approximately $27,883,250.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 13.45% of the stock is owned by company insiders.

A number of hedge funds have recently modified their holdings of the stock. Granahan Investment Management Inc. MA lifted its stake in shares of Spero Therapeutics by 67.0% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 555,614 shares of the company’s stock valued at $10,229,000 after purchasing an additional 222,975 shares in the last quarter. Patriot Financial Group Insurance Agency LLC acquired a new position in Spero Therapeutics during the 4th quarter valued at about $66,000. Royal Bank of Canada grew its stake in shares of Spero Therapeutics by 8,249.7% in the 3rd quarter. Royal Bank of Canada now owns 180,102 shares of the company’s stock worth $3,316,000 after purchasing an additional 177,945 shares during the last quarter. Barclays PLC increased its position in shares of Spero Therapeutics by 79.1% in the third quarter. Barclays PLC now owns 9,965 shares of the company’s stock worth $183,000 after acquiring an additional 4,401 shares in the last quarter. Finally, BlackRock Inc. increased its position in shares of Spero Therapeutics by 1.3% in the third quarter. BlackRock Inc. now owns 1,802,528 shares of the company’s stock worth $33,185,000 after acquiring an additional 23,706 shares in the last quarter. Hedge funds and other institutional investors own 69.36% of the company’s stock.

Spero Therapeutics Company Profile (Get Rating)

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease.

Featured Articles

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.